As we discussed here, the United States Supreme Court last week ruled that state law claims for failure to include an adequate warning on a pharmaceutical label are not preempted by the federal Food and Drug Administration’s (“FDA”) prior approval of the product’s label.  Wyeth v. Levine, No. 06-1249 (March 4, 2009).  EAPD has now issued a client advisory discussing implications for pharmaceutical companies that may be of further interest to underwriters, claims personnel and risk managers.  For a copy, please click here. 

If you would be interested in learning more about the decision or the area of product liability coverage and/or defense, please click on the “Email the Editor” button to the left and leave a message for follow-up by an EAPD attorney.